The OPTIMIZE trial tested Leronlimab, a monoclonal antibody that blocks HIV entry into cells, in people with multidrug-resistant HIV-1. In just one week, 64% of patients on Leronlimab saw a significant drop in their viral load compared to only 23% on placebo. After 24 weeks of treatment with Leronlimab plus optimized background therapy, most participants reached undetectable virus levels. The drug was well tolerated with mostly mild side effects. These results show Leronlimab’s potential as a powerful new option for patients who have exhausted standard HIV treatments.